このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Bolt Biotherapeutics 過去の業績

過去基準チェック /06

Bolt Biotherapeuticsの収益は年間平均-12.9%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 79.1%割合で増加しています。

主要情報

-12.9%

収益成長率

61.1%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	79.1%
株主資本利益率	-60.5%
ネット・マージン	-556.6%
前回の決算情報	31 Mar 2024

Recent updates

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

収支内訳

Bolt Biotherapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:BOLT 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	11	-63	23
31 Dec 23	8	-69	23
30 Sep 23	7	-71	23
30 Jun 23	7	-77	22
31 Mar 23	7	-81	22
31 Dec 22	6	-88	23
30 Sep 22	5	-95	22
30 Jun 22	3	-97	22
31 Mar 22	2	-98	20
31 Dec 21	1	-99	18
30 Sep 21	1	-102	15
30 Jun 21	0	-89	13
31 Mar 21	0	-77	11
31 Dec 20	0	-61	9
30 Sep 20	0	-39	9
30 Jun 20	0	-36	8
31 Mar 20	0	-32	6
31 Dec 19	0	-30	5

質の高い収益: BOLTは現在利益が出ていません。

利益率の向上: BOLTは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BOLTは利益が出ておらず、過去 5 年間で損失は年間12.9%の割合で増加しています。

成長の加速: BOLTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BOLTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: BOLTは現在利益が出ていないため、自己資本利益率 ( -60.51% ) はマイナスです。

Bolt Biotherapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Recent updates

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06